secwatch / observer

8-K filed January 12, 2026, 6:59 PM ET ticker VIR CIK 0001706431

other material confidence high sentiment positive materiality 0.75

Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027

Vir Biotechnology, Inc.

Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.
Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.
ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.
VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-001768
form_type: 8-K
ticker: VIR
cik: 0001706431
company_name: Vir Biotechnology, Inc.
filed_at: 2026-01-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.951262+00:00
generated_at: 2026-05-16T10:53:56.889251+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-001768
json_url: https://secwatch.observer/filing/0001628280-26-001768.json
markdown_url: https://secwatch.observer/filing/0001628280-26-001768.md
text_url: https://secwatch.observer/filing/0001628280-26-001768.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/0001628280-26-001768-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/vir-20260112.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Mid-America Apartments, L.P.

MAA May 2026 blended rents highest in 2 years; repurchased $50M shares

Mid-America Apartments, L.P. June 1, 2026, 4:20 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001628280-26-001768

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.